Diet Drug Gets Another Chance

Wed, 22 Feb 2012

drugs have not impressed American governmental health regulators in the last few years with numerous prospective medications having not been given approval and a further having been removed from the market.

The future of Qnexa, a new , lies with the FDA, with a meeting next Wednesday will decide the fate of this pill.

This will be the second time that the Food and Drug Administration is going to be hearing evidence for or against approving Qnexa.

The medication was denied approval in October 2010; the FDA cited possible safety problems.

Nonetheless, the FDA stated that Vivus, its manufacturer, needs to provide additional data as to whether or not the medication can cause birth defects and, if so, which ones.

Furthermore, the FDA has also asked for data on whether or not the slight increase in heart rate linked to this drug increases the risk of cardiovascular events, like and .
add to favouritesnewsletterlink to this pagesend to friendpost comments

Link to this page

Copy and Paste the following HTML into your page.